Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年1月23日
	新闻
	BlossomHill Therapeutics Begins Trial of BH-30643 in EGFR-, HER2-Mutant NSCLC Precision Medicine Online NEW YORK – BlossomHill Therapeutics on Wednesday said it has begun treating lung cancer patients with EGFR- or HER2-mutated tumors with its ... 标记为不相关
	Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab ... AACR Journals ... cancer, HER2-mutant lung cancer, and HER2 overexpressing solid tumors. Given the increasing utilization of T-DXd, we sought to determine how HER2 ... 标记为不相关
	Investigation of biometabolites and novel antimicrobial peptides derived from promising ... - PLOS PLOS ... lung cancer genes computationally. Muhammad Afzal, Mai Abdel Haleem A. Abusalah, Neelum Shehzadi, Muhammad Absar, Naveed Ahmed, Sarmir Khan ... 标记为不相关
	Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol PharmaTimes AstraZeneca receives positive recommendations for lung cancer treatments. 标记为不相关
	Roche Launches Clinical Mass Spec System in Europe; Targets H2 2025 for Move Into US 360Dx Data From TRACERx Study Boosts Evidence for Personalis' MRD Test Performance in Lung Cancer. Premium. Abbott, BioMérieux, Cepheid, Roche, Others ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈